Major adverse cardiovascular event

Last revised by Joachim Feger on 11 Dec 2021

Citation, DOI, disclosures and article data

Citation:

Feger J, Bell D, Major adverse cardiovascular event. Reference article, Radiopaedia.org (Accessed on 23 Apr 2024) https://doi.org/10.53347/rID-84714

DOI:

https://doi.org/10.53347/rID-84714

Permalink:

https://radiopaedia.org/articles/84714

rID:

84714

Article created:

2 Dec 2020, Joachim Feger ◉

Disclosures:

At the time the article was created Joachim Feger had no recorded disclosures.

View Joachim Feger's current disclosures

Last revised:

11 Dec 2021, Joachim Feger ◉

Disclosures:

At the time the article was last revised Joachim Feger had no recorded disclosures.

View Joachim Feger's current disclosures

Revisions:

6 times, by 2 contributors - see full revision history and disclosures

Systems:

Cardiac

Tags:

cases

Synonyms:

Major adverse cardiovascular events (MACEs)
Major adverse cardiovascular event (MACE)
MACE (major adverse cardiovascular event)
Major adverse clinical event (cardiac)

A major adverse cardiovascular event (MACE), forming part of the larger category of major adverse clinical events, refers to a combined or composite clinical endpoint that is used for outcome evaluations in clinical trials for cardiovascular research. A major adverse cardiovascular/clinical event is employed as a surrogate measure of the safety and effectiveness of a particular intervention.

In the context of percutaneous coronary interventions (PCI), a major adverse cardiovascular event has been defined as being one of the following ^1,2:

cardiovascular death
myocardial infarction
stent thrombosis
repeat revascularization including bypass graft

Since there is no standard definition of other adverse cardiovascular outcomes as e.g. stroke, heart failure, recurrent angina ^1,2.

History and etymology

The term MACE seems to have originated in the 1990s and was initially developed to relate primarily to percutaneous coronary interventions ^1-3. Although the terms "adverse cardiac event" and "adverse clinical event" predated MACE by several years, the former first appearing as a trial endpoint in the early 1980s and the latter in the late 1980s ^5,6.